Fadogia Agrestis, at 600 mg per day, consistently elevates libido, sperm production, and testosterone in men, but requires cycling to avoid testicular toxicity at high dosages.

Verdict: likely FALSE (90%)

Web Report: https://solsice.com/public/debates/fadogia-agrestis-at-600-mg-per-day-consistently-elevates-lib-c51624e50c16

---

This section provides a brief overview of the key arguments. You do not need to read the full detailed report below.

✅ Key PRO arguments:

1. ■Fadogia agrestis [5] contains phytochemicals that act as luteinizing hormone (LH [11]) stimulants, which trigger Leydig cells [10] in the testes to increase testosterone [23] biosynthesis [1], and a 600 mg/day dose provides a consistent stimulus sufficient to elevate serum testosterone [18] and libido [12].
2. ■The lack of large-scale human randomized controlled trials represents a gap in clinical literature rather than an absolute negation of efficacy, and pharmacological plausibility from mechanistic data still supports the supplement's effects on the HPG axis.
3. ■Conservation of the HPG axis between rodents and humans, combined with reproducible animal model results, provides a reasonable basis for projecting testosterone [23]-elevating effects to human users at 600 mg/day.

❌ Key ANTI arguments:

1. ■A 2019 systematic review [21] in the Journal of Dietary Supplements explicitly states there are no peer-reviewed [13], randomized controlled trials in humans demonstrating that Fadogia agrestis [5] supplementation increases testosterone [23] or libido [12], so the 'consistently elevates' claim is unsupported.
2. ■The affirmative substitutes animal physiological data for human clinical outcomes; the LH [11]-stimulation mechanisms cited are derived from rodent studies [17] where the HPG axis responds differently than in humans, violating the logical requirement for cross-species transfer.
3. ■An exhaustive case analysis of the proposition (testosterone [23] elevated vs. not elevated) shows the affirmative's conclusion fails in every branch because no human evidence establishes consistent elevation at 600 mg/day.

💭 Conclusion: False. The assertion that Fadogia agrestis [5] at 600 mg/day consistently elevates libido [12], sperm production, and testosterone [23] in men is not supported by human clinical evidence, as a 2019 systematic review [21] in the Journal of Dietary Supplements found no peer-reviewed [13] randomized controlled trials in humans demonstrating these effects. The affirmative's reliance on rodent HPG-axis data constitutes an invalid cross-species substitution, since the hypothalamic-pituitary-gonadal axis responds differently in rodents than in humans. Furthermore, the compound claim includes sub-claims about sperm production and cycling [3] to avoid testicular toxicity [22] that are equally unsupported by human data, weakening the overall assertion to its least-supported component. The negative side's exhaustive case analysis demonstrated that the affirmative's conclusion fails under every logical branch, and the judge assigned 90% confidence to the FALSE verdict.

---

🔬 DeepResearch Result: likely FALSE ❌ (90%)

Assertion: Fadogia Agrestis [5], at 600 mg per day, consistently elevates libido [12], sperm production, and testosterone [23] in men, but requires cycling [3] to avoid testicular toxicity [22] at high dosages.

Participating models: gemma-4-26b-a4b-it 💬👁️, glm-4.7-flash 💬

📊 Face-offs: 0 concluded TRUE, 1 concluded FALSE (1 face-offs, 3 models)
📊 Score by side: TRUE=0.00, FALSE=0.90

🏅 Model score changes:
minimax-m3 💬👁️: +9

✅ PRO Arguments:

1. ■Fadogia agrestis contains phytochemicals that act as luteinizing hormone (LH [11]) stimulants, which trigger Leydig cells [10] in the testes to increase testosterone biosynthesis [1], and a 600 mg/day dose provides a consistent stimulus sufficient to elevate serum testosterone [18] and libido. gemma-4-26b-a4b-it 💬👁️
2. ■The lack of large-scale human randomized controlled trials represents a gap in clinical literature rather than an absolute negation of efficacy, and pharmacological plausibility from mechanistic data still supports the supplement's effects on the HPG axis. gemma-4-26b-a4b-it 💬👁️
3. ■Conservation of the HPG axis between rodents and humans, combined with reproducible animal model results, provides a reasonable basis for projecting testosterone-elevating effects to human users at 600 mg/day. gemma-4-26b-a4b-it 💬👁️

❌ ANTI Arguments:

1. ■A 2019 systematic review [21] in the Journal of Dietary Supplements explicitly states there are no peer-reviewed [13], randomized controlled trials in humans demonstrating that Fadogia agrestis supplementation increases testosterone or libido, so the 'consistently elevates' claim is unsupported. glm-4.7-flash 💬
2. ■The affirmative substitutes animal physiological data for human clinical outcomes; the LH-stimulation mechanisms cited are derived from rodent studies [17] where the HPG axis responds differently than in humans, violating the logical requirement for cross-species transfer. glm-4.7-flash 💬
3. ■An exhaustive case analysis of the proposition (testosterone elevated vs. not elevated) shows the affirmative's conclusion fails in every branch because no human evidence establishes consistent elevation at 600 mg/day. glm-4.7-flash 💬
4. ■The compound claim includes sub-claims about sperm production and the cycling requirement to avoid testicular toxicity, none of which are supported by human clinical evidence, making the weakest sub-claim (and thus the entire assertion) untenable. glm-4.7-flash 💬

💭 Reasoning: False. The assertion that Fadogia agrestis at 600 mg/day consistently elevates libido, sperm production, and testosterone in men is not supported by human clinical evidence, as a 2019 systematic review in the Journal of Dietary Supplements found no peer-reviewed randomized controlled trials in humans demonstrating these effects. The affirmative's reliance on rodent HPG-axis data constitutes an invalid cross-species substitution, since the hypothalamic-pituitary-gonadal axis responds differently in rodents than in humans. Furthermore, the compound claim includes sub-claims about sperm production and cycling to avoid testicular toxicity that are equally unsupported by human data, weakening the overall assertion to its least-supported component. The negative side's exhaustive case analysis demonstrated that the affirmative's conclusion fails under every logical branch, and the judge assigned 90% confidence to the FALSE verdict.

📋 PRO Facts:
• Fadogia agrestis contains phytochemicals reported to stimulate luteinizing hormone (LH) in rodent studies.
• LH stimulation can trigger Leydig cells to biosynthesize testosterone via the HPG axis.
• The HPG axis is a conserved endocrine pathway present in both rodents and humans.

📋 ANTI Facts:
• A 2019 systematic review in the Journal of Dietary Supplements found no peer-reviewed, randomized controlled trials in humans demonstrating that Fadogia agrestis increases testosterone or libido.
• The LH-stimulation mechanisms cited for Fadogia agrestis are derived from rodent studies, where the HPG axis responds differently than in humans.
• No human clinical evidence supports the claim that 600 mg/day consistently elevates sperm production in men.
• No human clinical evidence establishes that cycling is required to avoid testicular toxicity at high dosages of Fadogia agrestis.

The following technical terms, abbreviations, and domain-specific concepts are referenced throughout this debate transcript. Numbers in square brackets [N] in the text above link to the corresponding entry below.

[1] biosynthesis — The enzymatic production of complex molecules within a living organism; in this debate, refers to the cellular manufacture of testosterone by Leydig cells.

[2] comparative endocrinology — The branch of biology that compares hormonal systems across different species; cited in the debate to argue whether rodent HPG-axis findings transfer to humans.

[3] cycling — In supplementation contexts, the practice of taking a compound for a defined period followed by an abstinence period, claimed in the debate to mitigate testicular toxicity from Fadogia agrestis.

[4] endogenous production — The synthesis of a substance (such as testosterone) by the body itself, as opposed to exogenous (external) administration.

[5] Fadogia agrestis — A plant species whose extracts are discussed in the debate as a putative testosterone- and libido-enhancing supplement.

[6] gonadotropin — A class of pituitary hormones (such as LH and FSH) that stimulate the gonads; mentioned in the debate as being influenced by Fadogia agrestis.

[7] hemolysis — The rupture or destruction of red blood cells; cited in the debate as a severe adverse effect observed in toxicological assessments of Fadogia agrestis.

[8] hormonal upregulation — An increase in the synthesis, secretion, or activity of a hormone; in the debate, refers to elevated testosterone output.

[9] hypothalamic-pituitary-gonadal (HPG) axis — The hormonal feedback loop connecting the hypothalamus, pituitary gland, and gonads that governs reproductive function and sex-steroid production.

[10] Leydig cells — Testosterone-producing cells located in the testes, stimulated by luteinizing hormone to synthesize testosterone.

[11] LH — luteinizing hormone — A pituitary gonadotropin that binds to receptors on Leydig cells to drive testosterone biosynthesis.

[12] libido — Sexual drive or desire; cited in the debate as one of the outcomes claimed to be elevated by Fadogia agrestis.

[13] peer-reviewed — Describing scholarly work that has been vetted by independent experts prior to publication; used in the debate to weigh the credibility of cited studies.

[14] phytochemical — A bioactive compound produced by a plant; in the debate, refers to the constituents of Fadogia agrestis that are claimed to act as LH stimulants.

[15] randomized controlled trials (RCTs) — Clinical study designs in which participants are randomly assigned to treatment or control groups; the debate notes the absence of human RCTs for Fadogia agrestis.

[16] reproductive markers — Measurable physiological indicators of reproductive function, such as serum testosterone levels and sperm output.

[17] rodent studies — Experiments conducted in rats or mice; the debate disputes whether their findings on Fadogia agrestis transfer to humans.

[18] serum testosterone — The concentration of testosterone measured in the liquid portion of blood, used as a clinical marker of androgen status.

[19] signaling pathways — Chains of molecular interactions within cells that transmit a signal from a receptor to an effector response; cited as the mechanism by which Fadogia agrestis allegedly enhances testosterone production.

[20] spermatogenesis — The biological process by which sperm cells are produced in the testes.

[21] systematic review — A structured literature survey that applies predefined methods to identify and synthesize all relevant studies on a question; cited in the debate regarding human evidence for Fadogia agrestis.

[22] testicular toxicity — Damage or harmful effects to the testes, including impaired spermatogenesis or hormonal function; cited as a risk of high-dose Fadogia agrestis.

[23] testosterone — The primary male sex steroid hormone, produced mainly by Leydig cells, that drives libido, spermatogenesis, and other androgenic effects.

[24] toxicological assessments — Studies evaluating the adverse effects of a substance on living organisms; cited in the debate to argue that Fadogia agrestis carries significant safety risks.

[25] transfer operator — A logical construct invoked in the debate to evaluate whether mechanistic findings from one species (rodents) can validly be applied to another (humans).